Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum

Timothy A. Bates; Hans C. Leier; Zoe L. Lyski; Savannah K. McBride; Felicity J. Coulter; Jules B. Weinstein; James R. Goodman; Zhengchun Lu; Sarah A.R. Siegel; Peter Sullivan; Matt Strnad; Amanda E. Brunton; David X. Lee; Andrew C. Adey; Benjamin N. Bimber; Brian J. O’Roak; Marcel E. Curlin; William B. Messer; Fikadu G. Tafesse

doi:10.1038/s41467-021-25479-6

Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum

Timothy A. Bates, Hans C. Leier, Zoe L. Lyski, Savannah K. McBride, Felicity J. Coulter, Jules B. Weinstein, James R. Goodman, Zhengchun Lu, Sarah A.R. Siegel, Peter Sullivan, Matt Strnad, Amanda E. Brunton, David X. Lee, Andrew C. Adey, Benjamin N. Bimber, Brian J. O’Roak, Marcel E. Curlin, William B. Messer, Fikadu G. Tafesse

Research output: Contribution to journal › Article › peer-review

83 Scopus citations

Abstract

SARS-CoV-2 and its variants continue to infect hundreds of thousands every day despite the rollout of effective vaccines. Therefore, it is essential to understand the levels of protection that these vaccines provide in the face of emerging variants. Here, we report two demographically balanced cohorts of BNT162b2 vaccine recipients and COVID-19 patients, from which we evaluate neutralizing antibody titers against SARS-CoV-2 as well as the B.1.1.7 (alpha) and B.1.351 (beta) variants. We show that both B.1.1.7 and B.1.351 are less well neutralized by serum from vaccinated individuals, and that B.1.351, but not B.1.1.7, is less well neutralized by convalescent serum. We also find that the levels of variant-specific anti-spike antibodies are proportional to neutralizing activities. Together, our results demonstrate the escape of the emerging SARS-CoV-2 variants from neutralization by serum antibodies, which may lead to reduced protection from re-infection or increased risk of vaccine breakthrough.

Original language	English (US)
Article number	5135
Journal	Nature communications
Volume	12
Issue number	1
DOIs	https://doi.org/10.1038/s41467-021-25479-6
State	Published - Dec 1 2021

ASJC Scopus subject areas

General Chemistry
General Biochemistry, Genetics and Molecular Biology
General Physics and Astronomy

Access to Document

10.1038/s41467-021-25479-6

Cite this

Bates, T. A., Leier, H. C., Lyski, Z. L., McBride, S. K., Coulter, F. J., Weinstein, J. B., Goodman, J. R., Lu, Z., Siegel, S. A. R., Sullivan, P., Strnad, M., Brunton, A. E., Lee, D. X., Adey, A. C., Bimber, B. N., O’Roak, B. J., Curlin, M. E., Messer, W. B., & Tafesse, F. G. (2021). Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum. Nature communications, 12(1), Article 5135. https://doi.org/10.1038/s41467-021-25479-6

Bates, TA, Leier, HC, Lyski, ZL, McBride, SK, Coulter, FJ, Weinstein, JB, Goodman, JR, Lu, Z, Siegel, SAR, Sullivan, P, Strnad, M, Brunton, AE, Lee, DX, Adey, AC , Bimber, BN , O’Roak, BJ , Curlin, ME , Messer, WB & Tafesse, FG 2021, 'Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum', Nature communications, vol. 12, no. 1, 5135. https://doi.org/10.1038/s41467-021-25479-6

@article{71839ea77f1940cab0610ca91724baa8,

title = "Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum",

abstract = "SARS-CoV-2 and its variants continue to infect hundreds of thousands every day despite the rollout of effective vaccines. Therefore, it is essential to understand the levels of protection that these vaccines provide in the face of emerging variants. Here, we report two demographically balanced cohorts of BNT162b2 vaccine recipients and COVID-19 patients, from which we evaluate neutralizing antibody titers against SARS-CoV-2 as well as the B.1.1.7 (alpha) and B.1.351 (beta) variants. We show that both B.1.1.7 and B.1.351 are less well neutralized by serum from vaccinated individuals, and that B.1.351, but not B.1.1.7, is less well neutralized by convalescent serum. We also find that the levels of variant-specific anti-spike antibodies are proportional to neutralizing activities. Together, our results demonstrate the escape of the emerging SARS-CoV-2 variants from neutralization by serum antibodies, which may lead to reduced protection from re-infection or increased risk of vaccine breakthrough.",

author = "Bates, {Timothy A.} and Leier, {Hans C.} and Lyski, {Zoe L.} and McBride, {Savannah K.} and Coulter, {Felicity J.} and Weinstein, {Jules B.} and Goodman, {James R.} and Zhengchun Lu and Siegel, {Sarah A.R.} and Peter Sullivan and Matt Strnad and Brunton, {Amanda E.} and Lee, {David X.} and Adey, {Andrew C.} and Bimber, {Benjamin N.} and O{\textquoteright}Roak, {Brian J.} and Curlin, {Marcel E.} and Messer, {William B.} and Tafesse, {Fikadu G.}",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = dec,

day = "1",

doi = "10.1038/s41467-021-25479-6",

language = "English (US)",

volume = "12",

journal = "Nature communications",

issn = "2041-1723",

publisher = "Nature Research",

number = "1",

}

TY - JOUR

T1 - Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum

AU - Bates, Timothy A.

AU - Leier, Hans C.

AU - Lyski, Zoe L.

AU - McBride, Savannah K.

AU - Coulter, Felicity J.

AU - Weinstein, Jules B.

AU - Goodman, James R.

AU - Lu, Zhengchun

AU - Siegel, Sarah A.R.

AU - Sullivan, Peter

AU - Strnad, Matt

AU - Brunton, Amanda E.

AU - Lee, David X.

AU - Adey, Andrew C.

AU - Bimber, Benjamin N.

AU - O’Roak, Brian J.

AU - Curlin, Marcel E.

AU - Messer, William B.

AU - Tafesse, Fikadu G.

PY - 2021/12/1

Y1 - 2021/12/1

N2 - SARS-CoV-2 and its variants continue to infect hundreds of thousands every day despite the rollout of effective vaccines. Therefore, it is essential to understand the levels of protection that these vaccines provide in the face of emerging variants. Here, we report two demographically balanced cohorts of BNT162b2 vaccine recipients and COVID-19 patients, from which we evaluate neutralizing antibody titers against SARS-CoV-2 as well as the B.1.1.7 (alpha) and B.1.351 (beta) variants. We show that both B.1.1.7 and B.1.351 are less well neutralized by serum from vaccinated individuals, and that B.1.351, but not B.1.1.7, is less well neutralized by convalescent serum. We also find that the levels of variant-specific anti-spike antibodies are proportional to neutralizing activities. Together, our results demonstrate the escape of the emerging SARS-CoV-2 variants from neutralization by serum antibodies, which may lead to reduced protection from re-infection or increased risk of vaccine breakthrough.

AB - SARS-CoV-2 and its variants continue to infect hundreds of thousands every day despite the rollout of effective vaccines. Therefore, it is essential to understand the levels of protection that these vaccines provide in the face of emerging variants. Here, we report two demographically balanced cohorts of BNT162b2 vaccine recipients and COVID-19 patients, from which we evaluate neutralizing antibody titers against SARS-CoV-2 as well as the B.1.1.7 (alpha) and B.1.351 (beta) variants. We show that both B.1.1.7 and B.1.351 are less well neutralized by serum from vaccinated individuals, and that B.1.351, but not B.1.1.7, is less well neutralized by convalescent serum. We also find that the levels of variant-specific anti-spike antibodies are proportional to neutralizing activities. Together, our results demonstrate the escape of the emerging SARS-CoV-2 variants from neutralization by serum antibodies, which may lead to reduced protection from re-infection or increased risk of vaccine breakthrough.

UR - http://www.scopus.com/inward/record.url?scp=85113821355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85113821355&partnerID=8YFLogxK

U2 - 10.1038/s41467-021-25479-6

DO - 10.1038/s41467-021-25479-6

M3 - Article

C2 - 34446720

AN - SCOPUS:85113821355

SN - 2041-1723

VL - 12

JO - Nature communications

JF - Nature communications

IS - 1

M1 - 5135

ER -

Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this